Proteomic characterization of head and neck cancer patient-derived xenografts

Hua Li, Sarah Wheeler, Yongseok Park, Zhenlin Ju, Sufi M. Thomas, Michele Fichera, Ann M. Egloff, Vivian W. Lui, Umamaheswar Duvvuri, Julie E. Bauman, Gordon Mills, Jennifer R. Grandis

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Despite advances in treatment approaches for head and neck squamous cell carcinoma (HNSCC), survival rates have remained stagnant due to the paucity of preclinical models that accurately reflect the human tumor. Patient-derived xenografts (PDX) are an emerging model system where patient tumors are implanted directly into mice. Increased understanding of the application and limitations of PDXs will facilitate their rational use. Studies to date have not reported protein profiles of PDXs. Therefore, we developed a large cohort of HNSCC PDXs and found that tumor take rate was not influenced by the clinical, pathologic, or processing features. Protein expression profiles, from a subset of the PDXs, were characterized by reverse-phase protein array and the data was compared with The Cancer Genome Atlas HNSCC data. Cluster analysis revealed that HNSCC PDXs were more similar to primary HNSCC than to any other tumor type. Interestingly, while a significant fraction of proteins were expressed similarly in both primary HNSCC and PDXs, a subset of proteins/phosphoproteins were expressed at higher (or lower) levels in PDXs compared with primary HNSCC. These findings indicate that the proteome is generally conserved in PDXs, but mechanisms for both positive and negative model selection and/or differences in the stromal components exist. Implications: Proteomic characterization of HNSCC PDXs demonstrates potential drivers for model selection and provides a framework for improved utilization of this expanding model system.

Original languageEnglish (US)
Pages (from-to)278-286
Number of pages9
JournalMolecular Cancer Research
Volume14
Issue number3
DOIs
StatePublished - Mar 1 2016
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Heterografts
Proteomics
Neoplasms
Proteins
Protein Array Analysis
Carcinoma, squamous cell of head and neck
Atlases
Phosphoproteins
Proteome
Cluster Analysis
Cell Survival
Survival Rate
Genome

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Li, H., Wheeler, S., Park, Y., Ju, Z., Thomas, S. M., Fichera, M., ... Grandis, J. R. (2016). Proteomic characterization of head and neck cancer patient-derived xenografts. Molecular Cancer Research, 14(3), 278-286. https://doi.org/10.1158/1541-7786.MCR-15-0354

Proteomic characterization of head and neck cancer patient-derived xenografts. / Li, Hua; Wheeler, Sarah; Park, Yongseok; Ju, Zhenlin; Thomas, Sufi M.; Fichera, Michele; Egloff, Ann M.; Lui, Vivian W.; Duvvuri, Umamaheswar; Bauman, Julie E.; Mills, Gordon; Grandis, Jennifer R.

In: Molecular Cancer Research, Vol. 14, No. 3, 01.03.2016, p. 278-286.

Research output: Contribution to journalArticle

Li, H, Wheeler, S, Park, Y, Ju, Z, Thomas, SM, Fichera, M, Egloff, AM, Lui, VW, Duvvuri, U, Bauman, JE, Mills, G & Grandis, JR 2016, 'Proteomic characterization of head and neck cancer patient-derived xenografts', Molecular Cancer Research, vol. 14, no. 3, pp. 278-286. https://doi.org/10.1158/1541-7786.MCR-15-0354
Li, Hua ; Wheeler, Sarah ; Park, Yongseok ; Ju, Zhenlin ; Thomas, Sufi M. ; Fichera, Michele ; Egloff, Ann M. ; Lui, Vivian W. ; Duvvuri, Umamaheswar ; Bauman, Julie E. ; Mills, Gordon ; Grandis, Jennifer R. / Proteomic characterization of head and neck cancer patient-derived xenografts. In: Molecular Cancer Research. 2016 ; Vol. 14, No. 3. pp. 278-286.
@article{d84a2023905644d49489e63b6dd79ddb,
title = "Proteomic characterization of head and neck cancer patient-derived xenografts",
abstract = "Despite advances in treatment approaches for head and neck squamous cell carcinoma (HNSCC), survival rates have remained stagnant due to the paucity of preclinical models that accurately reflect the human tumor. Patient-derived xenografts (PDX) are an emerging model system where patient tumors are implanted directly into mice. Increased understanding of the application and limitations of PDXs will facilitate their rational use. Studies to date have not reported protein profiles of PDXs. Therefore, we developed a large cohort of HNSCC PDXs and found that tumor take rate was not influenced by the clinical, pathologic, or processing features. Protein expression profiles, from a subset of the PDXs, were characterized by reverse-phase protein array and the data was compared with The Cancer Genome Atlas HNSCC data. Cluster analysis revealed that HNSCC PDXs were more similar to primary HNSCC than to any other tumor type. Interestingly, while a significant fraction of proteins were expressed similarly in both primary HNSCC and PDXs, a subset of proteins/phosphoproteins were expressed at higher (or lower) levels in PDXs compared with primary HNSCC. These findings indicate that the proteome is generally conserved in PDXs, but mechanisms for both positive and negative model selection and/or differences in the stromal components exist. Implications: Proteomic characterization of HNSCC PDXs demonstrates potential drivers for model selection and provides a framework for improved utilization of this expanding model system.",
author = "Hua Li and Sarah Wheeler and Yongseok Park and Zhenlin Ju and Thomas, {Sufi M.} and Michele Fichera and Egloff, {Ann M.} and Lui, {Vivian W.} and Umamaheswar Duvvuri and Bauman, {Julie E.} and Gordon Mills and Grandis, {Jennifer R.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1158/1541-7786.MCR-15-0354",
language = "English (US)",
volume = "14",
pages = "278--286",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Proteomic characterization of head and neck cancer patient-derived xenografts

AU - Li, Hua

AU - Wheeler, Sarah

AU - Park, Yongseok

AU - Ju, Zhenlin

AU - Thomas, Sufi M.

AU - Fichera, Michele

AU - Egloff, Ann M.

AU - Lui, Vivian W.

AU - Duvvuri, Umamaheswar

AU - Bauman, Julie E.

AU - Mills, Gordon

AU - Grandis, Jennifer R.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Despite advances in treatment approaches for head and neck squamous cell carcinoma (HNSCC), survival rates have remained stagnant due to the paucity of preclinical models that accurately reflect the human tumor. Patient-derived xenografts (PDX) are an emerging model system where patient tumors are implanted directly into mice. Increased understanding of the application and limitations of PDXs will facilitate their rational use. Studies to date have not reported protein profiles of PDXs. Therefore, we developed a large cohort of HNSCC PDXs and found that tumor take rate was not influenced by the clinical, pathologic, or processing features. Protein expression profiles, from a subset of the PDXs, were characterized by reverse-phase protein array and the data was compared with The Cancer Genome Atlas HNSCC data. Cluster analysis revealed that HNSCC PDXs were more similar to primary HNSCC than to any other tumor type. Interestingly, while a significant fraction of proteins were expressed similarly in both primary HNSCC and PDXs, a subset of proteins/phosphoproteins were expressed at higher (or lower) levels in PDXs compared with primary HNSCC. These findings indicate that the proteome is generally conserved in PDXs, but mechanisms for both positive and negative model selection and/or differences in the stromal components exist. Implications: Proteomic characterization of HNSCC PDXs demonstrates potential drivers for model selection and provides a framework for improved utilization of this expanding model system.

AB - Despite advances in treatment approaches for head and neck squamous cell carcinoma (HNSCC), survival rates have remained stagnant due to the paucity of preclinical models that accurately reflect the human tumor. Patient-derived xenografts (PDX) are an emerging model system where patient tumors are implanted directly into mice. Increased understanding of the application and limitations of PDXs will facilitate their rational use. Studies to date have not reported protein profiles of PDXs. Therefore, we developed a large cohort of HNSCC PDXs and found that tumor take rate was not influenced by the clinical, pathologic, or processing features. Protein expression profiles, from a subset of the PDXs, were characterized by reverse-phase protein array and the data was compared with The Cancer Genome Atlas HNSCC data. Cluster analysis revealed that HNSCC PDXs were more similar to primary HNSCC than to any other tumor type. Interestingly, while a significant fraction of proteins were expressed similarly in both primary HNSCC and PDXs, a subset of proteins/phosphoproteins were expressed at higher (or lower) levels in PDXs compared with primary HNSCC. These findings indicate that the proteome is generally conserved in PDXs, but mechanisms for both positive and negative model selection and/or differences in the stromal components exist. Implications: Proteomic characterization of HNSCC PDXs demonstrates potential drivers for model selection and provides a framework for improved utilization of this expanding model system.

UR - http://www.scopus.com/inward/record.url?scp=84962226262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962226262&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-15-0354

DO - 10.1158/1541-7786.MCR-15-0354

M3 - Article

C2 - 26685214

AN - SCOPUS:84962226262

VL - 14

SP - 278

EP - 286

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 3

ER -